Mayne Pharma is to launch doxycycline in the US

Company News

by Rachael Jones

Pharmaceutical company Mayne Pharma (ASX:MYX) is to launch doxycycline in the US.

The pills are a generic alternative to Monodox – an antibacterial for the treatment of a number of infections including severe acne.

The capsules can also be used to treat other skin conditions such as psoriasis.

Mayne Pharma directly markets more than 55 products and has a growing pipeline of around 30 drug products in the US markets.

According to reports – the annual US sales of doxycycline capsules were approximately $US30 million for the 12 months ending 31 January 2018.

Shares in Mayne Pharma (ASX:MYX) are down 1.96 per cent to $0.75
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.